Albumin-Stabilized Manganese Oxide/Semiconducting Polymer Nanocomposites for Photothermal-Chemodynamic Therapy of Hepatic Carcinoma

Qi Su†, Changcun Liu‡, Jingyi Zhu*, Mengbin Ding, Zhen Zhang, Jingchao Li* and Qin Zhang

1Department of Critical Care Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2Department of Nuclear Medicine, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 3School of Pharmaceutical Sciences, Nanjing Tech University, Nanjing, China, 4Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, China, 5Institute of Translational Medicine, Shanghai University, Shanghai, China

Hepatic carcinoma is one of the most common cancers worldwide, while its treatment remains a great challenge. Traditional therapeutic methods often have disadvantages such as limited therapeutic efficacy and potential side effects. In this study, we report the construction of bovine serum albumin (BSA)–stabilized manganese oxide (MnO₂)/semiconducting polymer (SP) nanocomposites to combine photothermal therapy (PTT) and chemodynamic therapy (CDT) for treatment of hepatic carcinoma in living mouse models. Such nanocomposites are composed of BSA, SP, and MnO₂ as the stabilizer, PTT, and CDT agent, respectively. SP produced local heat under near-infrared (NIR) laser irradiation for PTT, and MnO₂ nanoparticles mediated CDT in the tumor microenvironment, leading to apoptosis of cancer cells. Such nanocomposite-mediated combinational therapy showed a much higher efficacy in inhibiting growth of subcutaneous HepG2 tumors in nude mice than sole treatment. This study thus provides a multifunctional nanoplatform for safe and effective treatment of hepatic carcinoma.

Keywords: hepatic carcinoma, photothermal therapy, chemodynamic therapy, combinational therapy, nanocomposites

INTRODUCTION

Hepatic carcinoma has been the fifth common type of cancer and third common cause of cancer-related deaths over the world (Zhou et al., 2018; Liu et al., 2020; Qi et al., 2021). Traditional approaches for treatment of hepatic carcinoma include surgery, chemotherapy, and radiotherapy (Golubitschaja et al., 2016; Wang et al., 2019; Zhu et al., 2019). Surgery is still one of the first-choice treatments for hepatic carcinoma, but tumor recurrence rates after surgery are higher than 40%, which restricts the long-term survival of patients (Depalo et al., 2017). Although chemotherapy has exhibited a remarkable curative effect with great success in clinical practice, it often has disadvantages such as poor tumor specificity, high systemic toxicity, and adverse effects (Tian et al., 2010). Radiotherapy usually faces the common dilemmas of poor efficacy, severe side effects,
and radioresistance (De Ruysscher et al., 2019). Therefore, exploration of efficient and safe strategies for treatment of hepatic carcinoma is in high demand.

Unlike traditional treatment, photothermal therapy (PTT) utilizes photothermal conversion agents to convert light energy into heat energy, thereby increasing the temperature of the surrounding environment and causing the death of cancer cells (Hu et al., 2018; Jung et al., 2018; Liu et al., 2019). As external laser irradiation can precisely target tumor tissues, PTT can minimize the damage to the surrounding normal tissues and thus shows high specificity (Li et al., 2019; Li et al., 2020; Yuan et al., 2020). Chemodynamic therapy (CDT) is an emerging tumor treatment method that utilizes Fenton and Fenton-like reactions in the tumor microenvironment to generate highly toxic hydroxyl radicals (OH) for inducing cell apoptosis (Wang et al., 2020; Hao et al., 2021; Tian et al., 2021). CDT has high tumor specificity and selectivity and low toxicity in normal tissues, but the limited content of endogenous hydrogen peroxide (H$_2$O$_2$) and high concentrations of antioxidants in the tumor microenvironment can lead to unsatisfactory therapeutic effects (Cao et al., 2019; Ming et al., 2020; Yu et al., 2021). Since it is difficult for a single treatment method to achieve the desired therapeutic effect, a combination of different treatment modalities is expected to improve the antitumor efficacy (Li et al., 2018b; Hu et al., 2019; Chen et al., 2021). Therefore, the combination of PTT with CDT has not only shown high selectivity for cancer treatment but also improved therapeutic efficacy.

With the development of nanotechnology, a large number of nanoparticles with different functions and properties have been used as therapeutic agents for cancer treatment (Gai et al., 2018; Sahu et al., 2020; Siddique and Chow, 2020). Nanoparticles can improve the stability, water solubility, and pharmacokinetics of small-molecular anticancer drugs and allow the delivery of drugs into tumor sites for improved chemotherapy (Beigines et al., 2020; Manzano and Vallet-Regí, 2020; Yu et al., 2020). Some nanoparticles can generate heat or highly toxic reactive oxygen species (ROS) upon external stimuli or reactions with endogenous chemical stimuli in the tumor microenvironment to show therapeutic actions (Chen et al., 2016; Son et al., 2020; Tang et al., 2020). In addition, nanoparticles can mediate combinational therapy through integrating different therapeutic components into a single nanosystem (Zhang et al., 2017; Zhang et al., 2018; Shrestha et al., 2019). Therefore, nanoparticle-mediated combinational therapy should provide an alternative strategy for treatment of hepatic carcinoma.

Herein, we report the construction of bovine serum albumin (BSA)–stabilized manganese oxide (MnO$_2$)/semiconducting polymer (SP) nanocomposites for combinational PTT and CDT of hepatic carcinoma in living mouse models. BSA was utilized as both a reductant and a template to synthesize BSA-MnO$_2$ nanoparticles, which served as a stabilizer to construct BSA-MnO$_2$/SP nanocomposites (Figure 1A). MnO$_2$ nanoparticles have been utilized for cancer therapy as they can mediate Fenton-like reactions in the tumor microenvironment to generate OH (Ou et al., 2021). Due to its good biocompatibility and excellent optical property, SP can be used for PTT (Li et al., 2018a). Under 808 nm laser irradiation, MnO$_2$ and SP mediated the generation of OH and local heat in tumors for CDT and PTT, respectively. Such a combinational therapy showed an improved efficacy in completely inhibiting the growth of subcutaneous HepG2 tumors in nude mice (Figure 1B).
MATERIALS AND METHODS

Materials
BSA and SP were purchased from Sigma-Aldrich (St. Louis, United States). Singlet oxygen sensor green (SOSG) and the cell counting kit-8 (CCK-8) agent were purchased from Thermo Fisher Scientific (Invitrogen, United States) and Doidindo Laboratories (Kumamoto, Japan), respectively. RPMI 1640 medium, penicillin-streptomycin, and fetal bovine serum (FBS) were obtained from Gibco (Grand Island, NY, United States). Ultrapure water used in all experiments was prepared using a water purification system (PALL Cascada, MI, United States). All other chemicals were purchased from Sinopharm Chemical Reagent Co. Ltd. (Shanghai, China).

Synthesis of BSA-MnO2/SP Nanocomposites
BSA-MnO2 nanoparticles were synthesized according to the procedures reported previously (Liu et al., 2021; Chen et al., 2022). In brief, aqueous solution of KMnO4 (3 ml, 10.5 mg/ml) was dropwise added to BSA solution (7 ml, 35.7 mg/ml) under sonication, and the resulting solution was vigorously stirred at 37°C for 2 h. After purification via dialysis (molecular weight cutoff = 8–14 kDa), BSA-MnO2 nanoparticles were obtained. To synthesize BSA-MnO2/SP nanocomposites, SP dissolved in tetrahydrofuran (1 ml, 0.5 mg/ml) was rapidly injected into the solution of BSA-MnO2 nanoparticles, and the resulting solution was treated by sonication for 5 min. After removal of tetrahydrofuran via a nitrogen flow and filtration of the remaining solution via a 220 nm PVDF filter, BSA-MnO2/SP nanocomposites were obtained. To synthesize BSA/SP nanoparticles as control, SP dissolved in tetrahydrofuran (1 ml, 0.5 mg/ml) was rapidly injected into BSA solution under sonication for 5 min.

Characterization Techniques
Transmission electron microscope (TEM) images were obtained using a Tecnai G2 TEM (United States). Dynamic light scattering (DLS) and zeta potential measurement were conducted on a Zetasizer Nano-series (Nano-ZS90, Malvern, United Kindom). UV-vis spectra were obtained using a Persee spectrophotometer (TU-1810, Beijing, China). Fluorescence spectra were recorded on a fluorescence spectrophotometer (RF-6000, SHIMADZU, Japan).

Evaluation of Photothermal Property
To evaluate the photothermal property of BSA/SP and BSA-MnO2/SP, the solutions containing BSA/SP or BSA-MnO2/SP at an SP concentration of 100 µg/ml were irradiated by 808 nm laser at different power densities (0.5, 1.0, and 1.5 W/cm²) for 5 min. Thermal images were obtained using a thermal infrared camera, and the temperatures during laser irradiation were recorded. In addition, the solutions of BSA/SP or BSA-MnO2/SP at different SP concentrations (12.5, 25, 50, and 100 µg/ml) were irradiated by 808 nm laser at a power density of 1.0 W/cm² for 5 min to evaluate the influence of nanoparticle concentrations on temperature. Moreover, the solutions were treated by laser on/off at least five times to evaluate the photothermal stability of BSA/SP and BSA-MnO2/SP nanoparticles.

Evaluation of OH Generation Efficacy
The solutions containing BSA-MnO2 or BSA-MnO2/SP at a Mn concentration of 10 µg/ml were mixed with the solution of methylene blue (MB) with or without the addition of glutathione (GSH, 0.5 mM) and H2O2 (100 µM). After incubation for 10 min, the absorbance of the solutions was measured using a Persee spectrophotometer (TU-1810, Beijing, China). To evaluate PTT-amplified OH generation, the mixed solutions were irradiated by 808 nm laser at a power density of 1.0 W/cm² for 5 min, and then the absorbance of solutions was measured using a spectrophotometer.

In Vitro Cytotoxicity Assay
HepG2 cancer cells were cultured in RPMI 1640 cell culture medium containing penicillin and streptomycin and 10% FBS at 37°C. The cells were seeded in 96-well plates (1 × 10³ cells/well) and cultured for 24 h, and then the cells were incubated with BSA/SP or BSA-MnO2/SP nanoparticles at different SP concentrations (6.25, 12.5, 25, 50, and 100 µg/ml) for 24 h. The cell culture medium was discarded, the cells were carefully washed with phosphate buffer solution (PBS), and a fresh medium containing a 10% CCK-8 agent was added into each well; then the cells were incubated for another 4 h. After that, a CCK-8 assay was used to evaluate the cell viability. The cells treated with PBS were used as control.

In Vitro Therapeutic Efficacy Evaluation
HepG2 cells seeded in 96-well plates (1 × 10⁴ cells/well) were incubated with BSA/SP or BSA-MnO2/SP nanoparticles at SP concentration of 100 µg/ml with or without the addition of H2O2 (100 µM) for 24 h. Then laser irradiation (808 nm, 1.0 W/cm²) of cells was conducted for 5 min, and the cells were incubated for another 12 h. After that, a CCK-8 assay was used to evaluate the cell viability.

Establishment of HepG2 Tumor Models
Nude mice (female, 4–6 weeks) were purchased from JieSilie Laboratory Animal Co. Ltd. (Shanghai, China). All animal experiments were conducted according to the procedures permitted by the Institutional Anima Care and Treatment Committee of Donghua University. The suspension of HepG2 cells in PBS was subcutaneously injected into the right flank of each mouse (2 × 10⁶ cells/mouse). HepG2 tumor–bearing nude mice were used for in vivo experiments after 10 days of tumor implantation.

In Vivo PTT of Tumors
HepG2 tumor–bearing mice were randomly divided into two groups (n = 3), and PBS solutions of BSA/SP or BSA-MnO2/SP nanoparticles (20 µL, SP concentration = 250 µg/ml) were intratumorally administrated into tumor tissues. At 30 min after injection, the tumors were irradiated by 808 nm laser (1.0 W/cm²) for 10 min. During laser irradiation, a thermal camera was used to obtain thermal images of the mice, and the temperatures in the tumor sites were measured by analyzing
the thermal images. Temperature curves as a function of laser irradiating time were obtained.

**In Vivo Antitumor Efficacy Evaluation**
The HepG2 tumor–bearing mice were randomly divided into four groups: PBS, BSA-MnO2/SP, BSA/SP + laser, and BSA-MnO2/SP + laser ($n = 4$). The mice were intratumorally administered with 20 μl PBS and PBS solutions of BSA/SP or BSA-MnO2/SP nanoparticles (SP concentration = 250 μg/ml). For laser irradiation groups, the tumors were irradiated by 808 nm laser (1.0 W/cm²) for 10 min at 30 min after injection. After treatment, the sizes of the tumors and the body weights of mice were recorded every 2 days for 18 days. The volumes of the tumors were calculated as follows: $V = (\text{length}) \times (\text{width})^2/2$. The relative tumor volumes were calculated as $V/V_0$ ($V_0$ is the tumor volume at day 0). At day 18, the mice were sacrificed to extract tumors, and the tumor weights were measured.

**Statistical Analysis**
The data were expressed as mean ± standard deviation. The statistically significant differences were analyzed via unpaired student’s $t$-test. $^*p < 0.05$, $^**p < 0.01$, and $^***p < 0.001$ denoted statistical significance.

**RESULTS AND DISCUSSION**

**Preparation and Characterization of BSA-MnO2/SP Nanocomposites**
BSA-MnO2 nanoparticles were first synthesized with BSA acting as both a reductant and a template. TEM imaging showed that the formed BSA-MnO2 nanoparticles had a spherical morphology (Supplementary Figure S1). The hydrodynamic size and zeta potential of BSA-MnO2 nanoparticles were measured to be 7.2 nm and $-15.6$ mV, respectively (Supplementary Figure S2). BSA-MnO2 nanoparticles were then used as a stabilizer to prepare BSA-MnO2/SP nanocomposites through sonication. Poly(cyclopentadithiophene-alt-benzothiadiazole) with excellent optical property and photothermal conversion efficacy was used as the SP (Li et al., 2018b). The formed BSA-MnO2/SP nanocomposites showed a spherical morphology, as observed from the TEM image (Figure 2A). The hydrodynamic size of BSA-MnO2/SP nanocomposites measured by DLS was 73.5 nm, which was larger than that of BSA-SP nanoparticles (52.7 nm) (Figures 2B,C). The zeta potential of BSA-MnO2/SP nanocomposites was measured to be $-19.5$ mV, which was similar to that of BSA-SP nanoparticles ($-16.1$ mV) (Figure 2D). The optical properties of nanoparticles are important for their different applications (Peng and Chen, 2018; Peng et al., 2020a; Peng et al., 2020b), which were then investigated. The characteristic absorbance at 680 nm was observed in the absorbance spectra of both BSA-SP and BSA-MnO2/SP (Figure 2E). In addition, BSA-SP nanoparticles and BSA-MnO2/SP nanocomposites had similar fluorescence property, with the fluorescence emission at around 845 nm (Figure 2F). These results indicating that the existence of MnO2 nanoparticles did not obviously affect the optical properties of nanoparticles.
Evaluation of Photothermal Conversion Efficacy

To evaluate the photothermal conversion efficacy, the solutions containing nanoparticles were treated with 808 nm laser, and the temperatures of the solutions were recorded. At the same concentration, the temperatures of the solutions containing BSA-MnO₂/SP nanocomposites gradually increased under laser irradiation (Figure 3A). To confirm power density–dependent temperature increase, the commonly used laser densities (0.5, 1.0, and 1.5 W/cm²) were used. The temperature increased much more obviously at a higher power density of laser, which reached 36.2, 56.6, and 65.7°C after 5 min of laser irradiation at power densities of 0.5, 1.0, and 1.5 W/cm², respectively (Figure 3B). After 5 min of laser irradiation, the temperatures of the solutions reached the maximum. These results suggested that higher power density could lead to a higher temperature increase for BSA-MnO₂/SP nanocomposites. The power density–dependent temperature increase was also observed for BSA/SP nanoparticles (Figures 3C,D). At a power density of 1.0 W/cm², the temperature of the solutions containing BSA-MnO₂/SP nanocomposites increased diversely at different concentrations (Figure 3E). At concentrations of 12.5, 25, 50, and 100 μg/ml under 808 nm laser irradiation at a power density of 1.0 W/cm², the temperature increased to 34.0, 41.1, 48.7, and 56.6°C after 5 min of laser irradiation, respectively (Figure 3F). Similar tendencies were also observed for BSA/SP nanoparticles, and the temperature increase was much more obvious at a higher concentration (Figures 3G,H).

The photothermal stability of nanoparticles was then evaluated. After five cycles of laser on/off, the temperature increases of solutions containing BSA/SP nanoparticles and BSA-MnO₂/SP nanocomposites did not have any decreases (Figure 3I), suggesting their excellent photothermal stability. The slight increases in maximal temperatures for solutions after more cycles of laser irradiation might be due to high
temperature–mediated evaporation of water to increase the concentrations of nanoparticles. In addition, the temperatures were similar for BSA/SP nanoparticles and BSA-MnO₂/SP nanocomposites at the same concentration and laser irradiation time. This indicated that BSA/SP nanoparticles and BSA-MnO₂/SP nanocomposites had similar photothermal conversion efficacy.

Evaluation of OH Generation Efficacy

The generation of OH via MnO₂-mediated Fenton-like reaction was evaluated using MB as the indicator. The characteristic absorption peak of MB at 665 nm did not have obvious changes for GSH + MB + H₂O₂ and BSA-MnO₂ + GSH + MB groups, while that was obviously reduced for the BSA-MnO₂ + GSH + MB + H₂O₂ group (Figure 4A), which suggested the generation of OH via Fenton-like reaction for BSA-MnO₂ nanoparticles. The characteristic absorption peak of MB was still high in the BSA-MnO₂/SP + GSH + MB group, which was obviously reduced in the BSA-MnO₂/SP + GSH + MB + H₂O₂ group (Figure 4B), indicating the OH generation for BSA-MnO₂/SP nanocomposites. In addition, the decrease in the characteristic absorption peak of MB in the BSA-MnO₂/SP + GSH + MB + H₂O₂ group was much more obvious after 808 nm laser irradiation (Figure 4C), which suggested the enhanced generation of OH after 808 nm laser irradiation. These results suggested that the Fenton-like reaction effect of BSA-MnO₂/SP nanocomposites could be accelerated by the PTT-mediated temperature rise, and thus, PTT and CDT showed a synergistic effect.

Evaluation of In Vitro Therapeutic Efficacy

The in vitro cytotoxicity of BSA/SP nanoparticles and BSA-MnO₂/SP nanocomposites was evaluated using the CCK-8 assay. After treatment with BSA/SP nanoparticles for 24 h, the cell viability of HepG2 cells did not have obvious changes even at a high concentration of 100 μg/ml when compared to the control group (Figure 5A), which indicated the good cytocompatibility of BSA/SP nanoparticles. After incubation with BSA-MnO₂/SP nanocomposites, the cell viability reduced with the increase in concentration, which should be due to the slight cytotoxicity induced by MnO₂ nanoparticles.
The in vitro therapeutic efficacy of nanoparticles was then investigated (Figure 5B). Without 808 nm laser irradiation, the cell viability of HepG2 cells did not have obvious changes after treatment with BSA/SP nanoparticles and H$_2$O$_2$, while that significantly reduced to 79.5% after treatment with BSA-MnO$_2$/SP nanocomposites and H$_2$O$_2$, suggesting the generation of highly toxic OH for BSA-MnO$_2$/SP nanocomposite–mediated CDT. With 808 nm laser irradiation, the cell viability of HepG2 cells after treatment with BSA/SP nanoparticles and H$_2$O$_2$ was only 6.3% due to BSA/SP nanoparticle–mediated PTT. In addition, the cell viability of HepG2 cells after treatment with BSA/SP nanoparticles and H$_2$O$_2$ was only 6.3% due to BSA/SP nanoparticle–mediated PTT. In addition, the cell viability of HepG2 cells after treatment with BSA-MnO$_2$/SP nanocomposites and H$_2$O$_2$ with 808 nm laser irradiation was 0.87%, which was 91.3- and 7.2-fold lower than that in the BSA-MnO$_2$/SP + H$_2$O$_2$ and BSA/SP + H$_2$O$_2$ + laser group, respectively. These results indicated the amplified in vitro therapeutic efficacy of BSA-MnO$_2$/SP nanocomposite–mediated combinational PTT and CDT compared to sole CDT and PTT.

Evaluation of In Vivo Antitumor Efficacy

To evaluate the in vivo therapeutic efficacy, HepG2 tumor–bearing mice were randomly divided into four groups, and PBS, BSA/SP nanoparticles, or BSA-MnO$_2$/SP nanocomposites were locally injected into tumor sites, followed by irradiation of tumors with 808 nm laser (1.0 W/cm$^2$). Although the temperatures of nanoparticle solutions reached the maximum after 5 min of laser irradiation, a longer period of laser irradiation (10 min) was conducted to achieve ideal therapeutic efficacy. Under laser irradiation, the temperatures of tumor sites gradually increased with the laser irradiating time for both BSA/SP– and BSA-MnO$_2$/SP–injected mice (Figure 6A). The temperatures at different irradiating times for these two groups were similar, which reached the maximum (around 50.2°C) after 10 min of laser irradiation (Figure 6B). Note that the temperature of tumor sites for PBS-injected mice did not have obvious changes under laser irradiation (Supplementary Figure S3). These results suggested that BSA/SP and BSA-MnO$_2$/SP showed a similar in vivo PTT effect.

The in vivo therapeutic efficacy was evaluated by monitoring tumor growth. The tumor growth of BSA-MnO$_2$/SP–injected mice without laser irradiation was inhibited by 2.2-fold compared to that in control mice (Figure 6C), which should be due to the CDT effect. The tumor growth was inhibited by 2.4-fold after BSA/SP nanoparticle injection with 808 nm laser irradiation because of the PTT effect. It should be noteworthy that the growth of tumors was completely inhibited after BSA-
MnO2/SP nanocomposite injection and laser irradiation, which was due to the combinational action of PTT and CDT. After treatment for 18 days, no tumors were observed for the BSA-MnO2/SP + laser group, and the tumors in the BSA-MnO2/SP and BSA/SP + laser groups were smaller than those in the control group (Figure 6D). The tumor weight in the BSA-MnO2/SP + laser group was 0 g, while that was 0.43, 0.23, and 0.18 g for the control, BSA-MnO2/SP, and BSA/SP + laser group, respectively (Figure 6E). These results suggested that BSA-MnO2/SP after laser irradiation showed the highest antitumor efficacy due to the combinational action of CDT and PDT. In addition, the body weight of mice after different treatments remained nearly unchanged (Supplementary Figure S4), indicating that BSA-MnO2/SP-mediated therapy did not cause significant toxicity.

CONCLUSION

We have reported the construction of BSA-MnO2/SP nanocomposites for combinational PTT and CDT of hepatic carcinoma in living mouse models. Such BSA-MnO2/SP nanocomposites could be synthesized via a facile two-step procedure. The formed BSA-MnO2/SP nanocomposites showed a high photothermal conversion efficacy under 808 nm laser irradiation and efficient OH generation efficacy via a Fenton-like reaction. By mediating the combinational action of PTT and CDT, BSA-MnO2/SP nanocomposites led to much higher efficacy in killing HepG2 cancer cells in vitro than to their counterparts. Such a treatment strategy could afford an obviously enhanced antitumor efficacy in inhibiting the growth of subcutaneous HepG2 tumors in living mice. In view of the flexible and facile construction of nanocomposites, this nanoplateform can be integrated with other therapeutic components (such as chemodrugs and immunotherapeutic drugs) to achieve multimodal therapy of different types of tumors. By modifying the targeting ligands on the surface to increase their accumulation into tumor sites after systematic administration, these nanocomposites can be used for targeted treatment of tumors.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The animal study was reviewed and approved by the Institutional Animal Care and Treatment Committee of Donghua University.

AUTHOR CONTRIBUTIONS

JZ, JL, and QZ, the corresponding authors, contributed toward conception, design of the study, and revision of the manuscript; JZ, QS, and CL contributed toward acquisition, analysis, and interpretation of the data and drafting of the article. MD and ZZ contributed toward acquisition of the data and analysis. All authors read and approved the final manuscript.

FUNDING

This study was supported by the Science and Technology Commission of Shanghai Municipality (22ZR1424900, 22ZR1401100, 20DZ2254900) and the Fundamental Research Funds for the Central Universities (2232021A-05).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fbioe.2022.919235/full#supplementary-material

REFERENCES

Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., et al. (2020). Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials 10, 1403. doi:10.3390/nano10071403

Cao, S., Fan, J., Sun, W., Li, F., Li, K., Tai, X., et al. (2019). A Novel Mn-Cu Bimetallic Complex for Enhanced Chemodynamic Therapy with Simultaneous Glutathione Depletion. Chem. Commun. 55, 12956–12959. doi:10.1039/c9cc06040e

Chen, T., Chu, Q., Li, M., Han, G., and Li, X. (2021). Fe3O4@Pt Nanoparticles to Enable Combinational Electrodynamic/chemodynamic Therapy. J. Nanobiotechnol. 19, 206. doi:10.1186/s12951-021-00957-7

Chen, W., Zhang, C., Chen, D., Li, Y., Wu, S., Xu, C., et al. (2022). Tumor Redox Microenvironment Modulating Composite Hydrogels for Enhanced Sonodynamic Therapy of Colorectal Cancer. J. Mat. Chem. B 10, 1960–1968. doi:10.1039/d2tb00170e

Chen, Y.-W., Su, Y.-L., Hu, S.-H., and Chen, S.-Y. (2016). Functionalized Graphene Nanocomposites for Enhancing Photothermal Therapy in Tumor Treatment. Adv. Drug Deliv. Rev. 105, 190–204. doi:10.1016/j.addr.2016.05.022

De Ruyscher, D., Niedermann, G., Burnet, N. G., Siva, S., Lee, A. W. M., and Hegi-Johnson, F. (2019). Radiotherapy Toxicity. Nat. Rev. Dis. Prim. 5, 13. doi:10.1038/s41572-019-0064-5

Depalo, N., Iacobazzi, R. M., Valente, G., Arduino, I., Villa, S., Canepa, F., et al. (2017). Sorafenib Delivery Nanoplatform Based on Superparamagnetic Iron Oxide Nanoparticles Magnetically Targets Hepatocellular Carcinoma. Nano Res. 10, 2431–2448. doi:10.1007/s12274-017-1444-3

Gai, S., Yang, G., Yang, P., He, F., Lin, J., Jin, D., et al. (2018). Recent Advances in Functional Nanomaterials for Light-Triggered Cancer Therapy. Nano today 19, 146–187. doi:10.1016/j.nantod.2018.02.010

Golubnitschaja, O., Yeghiazaryan, K., Stricker, H., Trog, D., Schild, H. H., and Berliner, L. (2016). Patients with Hepatic Breast Cancer Metastases Demonstrate Highly Specific Profiles of Matrix Metalloproteinases MMP-2 and MMP-9 after SIRT Treatment as Compared to Other Primary and Secondary Liver Tumours. BMC Cancer 16, 357. doi:10.1186/s12885-016-2382-2

Hao, Y.-N., Zhang, W.-X., Gao, Y.-R., Wei, Y.-N., Shu, Y., and Wang, J.-H. (2021). State-of-the-art Advances of Copper-Based Nanostuctures in the Enhancement of Chemodynamic Therapy. J. Mat. Chem. B 9, 250–266. doi:10.1039/d0tb02360d

The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fbioe.2022.919235/full#supplementary-material
